Literature DB >> 7449133

Hepatic collagenolytic cathepsin in patients with chronic liver disease.

Y Murawaki, C Hirayama.   

Abstract

Human hepatic collagenolytic cathepsin consisted of a major component having a molecular weight of 25 000 and a minor one of 35 000; the former is indistinguishable for cathepsin B in its enzymatic properties. Hepatic collagenolytic cathepsin increased in chronic active liver disease in proportion to hepatic hydroxyproline content. The ratio of collagenolytic cathepsin to hepatic hydroxyproline content remained within the normal range in chronic hepatitis, but decreased significantly in cirrhosis. These results suggest that collagenolytic cathepsin participates, at least partly, in the progress of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7449133     DOI: 10.1016/0009-8981(80)90300-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Cellular sensitivity to collagen in liver disease.

Authors:  H Sawada; T Suou; C Hirayama
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

2.  Cathepsin D-like activity in neutrophils and monocytes.

Authors:  J Levy; G B Kolski; S D Douglas
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

3.  Human liver cathepsin L.

Authors:  R W Mason; G D Green; A J Barrett
Journal:  Biochem J       Date:  1985-02-15       Impact factor: 3.857

4.  Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers.

Authors:  Sami A Gabr; Ahmad H Alghadir
Journal:  Virusdisease       Date:  2013-11-30

5.  Granulocyte collagenase and cathepsin B in patients with cancer of digestive organs.

Authors:  K Tanimoto; Y Murawaki; C Hirayama
Journal:  Gastroenterol Jpn       Date:  1984-12

6.  Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats.

Authors:  Masaru Ueki; Masahiko Koda; Satoru Yamamoto; Yoshiko Matsunaga; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2006-11-09       Impact factor: 6.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.